Meeting News Coverage

PEARL-II, III: High SVR rates met in HCV genotype 1b patients

WASHINGTON, D.C. — A majority of patients with hepatitis C virus infection genotype 1b achieved sustained virologic response at 12 weeks during treatment with a three direct-acting antiviral regimen with or without ribavirin, according to data presented at ICAAC 2014.

David E. Bernstein, MD, chief of hepatology at Hofstra North Shore-Long Island Jewish School of Medicine, and colleagues analyzed pooled data from noncirrhotic patients with HCV genotype 1b (n=605) enrolled in the PEARL-II and III phase 3 trials undergoing treatment with a three direct-acting antiviral (3D) regimen. Patients were assigned ABT-450/ritonavir/ombitasvir (150 mg/100 mg/25 mg once daily) and dasabuvir (250 mg twice daily) with (n=298) or without ribavirin (RBV; n=300) for 12 weeks. Final analysis included data on 598 patients; 419 were treatment naive.

David E. Bernstein

Researchers wrote that 98.7% of patients assigned 3D plus RBV reached sustained virologic response (SVR), while 99.3% of patients who received just 3D met SVR at 12 weeks. One patient from the 3D/RBV group experienced viral breakthrough, while two others discontinued treatment due to an adverse event. All patients in the 3D group completed therapy. Adverse events occurred more frequently in the 3D/RBV group (240 vs. 214).

“Ninety-nine percent of treatment-naive and treatment-experienced HCV genotype 1b-infected patients without cirrhosis receiving the 3D regimen with or without ribavirin achieved an SVR12,” Bernstein said during his presentation.

For more information:

Bernstein D. Abstract V-672. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 5-9, 2014; Washington, D.C.

Disclosure: Visit the ICAAC website for a full list of relevant financial disclosures.

WASHINGTON, D.C. — A majority of patients with hepatitis C virus infection genotype 1b achieved sustained virologic response at 12 weeks during treatment with a three direct-acting antiviral regimen with or without ribavirin, according to data presented at ICAAC 2014.

David E. Bernstein, MD, chief of hepatology at Hofstra North Shore-Long Island Jewish School of Medicine, and colleagues analyzed pooled data from noncirrhotic patients with HCV genotype 1b (n=605) enrolled in the PEARL-II and III phase 3 trials undergoing treatment with a three direct-acting antiviral (3D) regimen. Patients were assigned ABT-450/ritonavir/ombitasvir (150 mg/100 mg/25 mg once daily) and dasabuvir (250 mg twice daily) with (n=298) or without ribavirin (RBV; n=300) for 12 weeks. Final analysis included data on 598 patients; 419 were treatment naive.

David E. Bernstein

Researchers wrote that 98.7% of patients assigned 3D plus RBV reached sustained virologic response (SVR), while 99.3% of patients who received just 3D met SVR at 12 weeks. One patient from the 3D/RBV group experienced viral breakthrough, while two others discontinued treatment due to an adverse event. All patients in the 3D group completed therapy. Adverse events occurred more frequently in the 3D/RBV group (240 vs. 214).

“Ninety-nine percent of treatment-naive and treatment-experienced HCV genotype 1b-infected patients without cirrhosis receiving the 3D regimen with or without ribavirin achieved an SVR12,” Bernstein said during his presentation.

For more information:

Bernstein D. Abstract V-672. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 5-9, 2014; Washington, D.C.

Disclosure: Visit the ICAAC website for a full list of relevant financial disclosures.

    See more from ICAAC 2014